GLUE vs. DYN, ABCL, WVE, AMPH, NAGE, ELVN, PAHC, CRMD, VERV, and NTLA
Should you be buying Monte Rosa Therapeutics stock or one of its competitors? The main competitors of Monte Rosa Therapeutics include Dyne Therapeutics (DYN), AbCellera Biologics (ABCL), WAVE Life Sciences (WVE), Amphastar Pharmaceuticals (AMPH), Niagen Bioscience (NAGE), Enliven Therapeutics (ELVN), Phibro Animal Health (PAHC), CorMedix (CRMD), Verve Therapeutics (VERV), and Intellia Therapeutics (NTLA). These companies are all part of the "pharmaceutical products" industry.
Monte Rosa Therapeutics vs. Its Competitors
Monte Rosa Therapeutics (NASDAQ:GLUE) and Dyne Therapeutics (NASDAQ:DYN) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, valuation, media sentiment, risk, earnings, analyst recommendations, dividends and institutional ownership.
Monte Rosa Therapeutics has a net margin of 3.86% compared to Dyne Therapeutics' net margin of 0.00%. Monte Rosa Therapeutics' return on equity of 2.65% beat Dyne Therapeutics' return on equity.
Monte Rosa Therapeutics has a beta of 1.41, meaning that its stock price is 41% more volatile than the S&P 500. Comparatively, Dyne Therapeutics has a beta of 1.08, meaning that its stock price is 8% more volatile than the S&P 500.
80.0% of Monte Rosa Therapeutics shares are held by institutional investors. Comparatively, 96.7% of Dyne Therapeutics shares are held by institutional investors. 6.9% of Monte Rosa Therapeutics shares are held by company insiders. Comparatively, 14.1% of Dyne Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Monte Rosa Therapeutics presently has a consensus price target of $15.33, indicating a potential upside of 224.17%. Dyne Therapeutics has a consensus price target of $41.13, indicating a potential upside of 360.01%. Given Dyne Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Dyne Therapeutics is more favorable than Monte Rosa Therapeutics.
Monte Rosa Therapeutics has higher revenue and earnings than Dyne Therapeutics. Dyne Therapeutics is trading at a lower price-to-earnings ratio than Monte Rosa Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Dyne Therapeutics had 18 more articles in the media than Monte Rosa Therapeutics. MarketBeat recorded 18 mentions for Dyne Therapeutics and 0 mentions for Monte Rosa Therapeutics. Monte Rosa Therapeutics' average media sentiment score of 1.89 beat Dyne Therapeutics' score of 0.43 indicating that Monte Rosa Therapeutics is being referred to more favorably in the media.
Summary
Monte Rosa Therapeutics beats Dyne Therapeutics on 9 of the 16 factors compared between the two stocks.
Get Monte Rosa Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for GLUE and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding GLUE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Monte Rosa Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:GLUE) was last updated on 7/3/2025 by MarketBeat.com Staff
